Analytical Data
-
基因名
CCL22
- Application
-
别名
CCL22；MDC；SCYA22；C-C motif chemokine 22
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O00626
-
表达区间
25-93aa
-
氨基酸序列
GPYGANMEDSVCCRDYVRYRLPLRVVKHFYWTSDSCPRPGVVLLTFRDKE ICADPRVPWVKMILNKLSQ
-
分子量
8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL22, also known as macrophage-derived chemokine (MDC), is a member of the CC chemokine family that plays a vital role in immune response regulation. It is primarily involved in the recruitment of specific immune cells, particularly T-helper 2 (Th2) cells and regulatory T cells (Tregs), to sites of inflammation and tumors. Research has shown that CCL22 is overexpressed in various cancer types, contributing to tumor evasion of the immune system by promoting Treg migration, thus limiting anti-tumor immune responses. Additionally, CCL22 has been implicated in chronic inflammatory conditions and allergic responses. Understanding the biological functions of CCL22 and its signaling mechanisms offers potential therapeutic avenues for enhancing anti-tumor immunity and modulating inflammatory diseases. The production of recombinant CCL22 protein facilitates further study into its biochemical properties, receptor interactions, and role in immune cell migration and activation. This research could ultimately inform the design of novel immunotherapies or targeted treatments aimed at manipulating CCL22 levels to influence immune responses favorably. As such, the study of recombinant CCL22 holds significant promise for advancing our understanding of immune regulation and developing innovative approaches to cancer and inflammatory diseases.
